ZELNATE ON ARRIVAL

Zelnate® DNA Immunostimulant on Arrival with MLV Vaccine on Arrival or Delayed1

Objective

Examine how Zelnate, when used on arrival, may improve health and performance outcomes. Observe the potential benefits of delaying the MLV vaccine until after the initial stress and Mannheimia haemolytica challenges are experienced.

Study Procedures

In this study, a total of 5,179 calves were divided into 4 groups and placed on trial:

  • Average of 86 calves per pen and average processing weight of 624 lbs
  • All groups administered Presponse® SQ and Micotil® (tilmicosin) Injection on arrival
  • All groups administered Pyramid® 5 MLV vaccine after a delay of ~30 days on feed (DOF)

Group 1 received normal processing protocols of administering a MLV vaccine (Pyramid® 5) both on arrival and after ~30 DOF. “Delayed MLV” Groups 3 & 4 were only administered the MLV vaccine after the ~30 day delay. Groups 2 & 4 were administered Zelnate on arrival.

On arrival After 30 DOF (± 5 days)
Group 1: Arrival MLV (no Zelnate) MLV MLV
Group 2: Arrival MLV & Arrival Zelnate MLV & Zelnate MLV
Group 3: Delayed MLV (no Zelnate) - MLV
Group 4: Delayed MLV & Arrival Zelnate Zelnate MLV

Various performance parameters including mortality were measured at 60 DOF, 116 DOF and study close-out.

SWIPE TO SEE MORE

More info >

Results

Zelnate significantly reduced overall mortality at every measured time frame. Zelnate also significantly reduced BRD mortality at 60 days and 116 days, and followed the same trend at close-out (P=0.06).1

Zelnate showed a trend in reducing the BRD case fatality rate throughout the study, although not statistically significant. Delaying the MLV significantly reduced 2nd BRD treatments at all three time frames, and significantly reduced BRD re-treatment risk at 116 days and close-out.1

Health at 60 Days on feed (DOF)*

Group 1 Arrival MLV (no Zelnate) Group 2 Arrival MLV & Arrival Zelnate Group 3 Delayed MLV (no Zelnate) Group 4 Delayed MLV & Arrival Zelnate P value for MLV (1+2 vs 3+4) P value for Zelnate (1+3 vs 2+4)
BRD Morbidity (1 Treatment), % 23.17 21.78 22.92 22.92 0.70 0.55
BRD 2 Treatments, % 9.39 9.67 8.36 7.49 0.04 0.66
BRD 3 Treatments, % 4.98 3.95 4.34 3.53 0.35 0.10
BRD Case Fatality, % 14.03 11.63 11.88 8.61 0.16 0.12
BRD Mortality, % 3.45 2.54 2.85 1.98 0.19 0.05
Overall Mortality, % 3.79 2.79 3.26 2.15 0.20 0.03

Initial analysis showed no interaction between Pyramid® and Zelnate.

Health at 116 Days on feed (DOF)*

Group 1 Arrival MLV (no Zelnate) Group 2 Arrival MLV & Arrival Zelnate Group 3 Delayed MLV (no Zelnate) Group 4 Delayed MLV & Arrival Zelnate P value for MLV (1+2 vs 3+4) P value for Zelnate (1+3 vs 2+4)
BRD Morbidity (1 Treatment), % 24.76 23.82 24.83 24.43 0.78 0.58
BRD 2 Treatments, % 10.04 10.62 9.09 8.15 0.04 0.76
BRD 3 Treatments, % 5.51 4.85 5.10 3.99 0.27 0.13
BRD Retreatment, % 43.95 46.78 39.48 37.06 0.01 0.96
BRD Case Fatality, % 16.24 13.19 13.78 9.97 0.13 0.07
BRD Mortality, % 4.22 3.22 3.54 2.44 0.13 0.04
Overall Mortality, % 4.99 3.75 4.30 2.67 0.08 <0.01
BRD Removals, % 0.63 0.68 0.46 0.46 0.27 0.90

Initial analysis showed no interaction between Pyramid® and Zelnate.

Health at close-out*

Group 1 Arrival MLV (no Zelnate) Group 2 Arrival MLV & Arrival Zelnate Group 3 Delayed MLV (no Zelnate) Group 4 Delayed MLV & Arrival Zelnate P value for MLV (1+2 vs 3+4) P value for Zelnate (1+3 vs 2+4)
BRD Morbidity (1 Treatment), % 25.50 25.16 26.03 25.18 0.82 0.63
BRD 2 Treatments, % 11.05 11.01 9.64 8.93 0.04 0.63
BRD 3 Treatments, % 5.79 5.50 5.53 4.35 0.24 0.22
BRD Retreatment Risk†, % 43.59 44.35 37.95 36.17 0.01 0.84
BRD Case Fatality, % 16.08 13.11 13.44 10.28 0.14 0.10
BRD Mortality, % 4.36 3.36 3.61 2.65 0.15 0.06
Overall Mortality, % 5.88 5.02 5.35 3.79 0.13 0.04
BRD Removals (Chronic), % 0.68 0.87 0.62 0.81 0.78 0.39
BRD Outs (Deads + Removals), % 4.98 4.21 4.17 3.47 0.16 0.18
Total Outs (Deads + Removals), % 6.88 6.16 6.34 5.26 0.27 0.17

Initial analysis showed no interaction between Pyramid® and Zelnate.

†BRD cases (1st treatments) that were re-treated for BRD.

SWIPE TO SEE MORE

Zelnate consistently improved survivability resulting in a 22% reduction in overall death loss, regardless of on arrival or delayed MLV.1

Mortality at 60 Days on feed (DOF): Without Zelnate vs. with Zelnate

Mortality Chart 60 DOF

At 60 DOF, results for Zelnate-treated calves showed a 30.2% reduction in total mortality and a 28.4% reduction in BRD mortality compared to calves not treated with Zelnate.1

Mortality at 116 Days on feed (DOF): Without Zelnate vs. with Zelnate

Mortality Chart 116 DOF

At 116 DOF, results for Zelnate-treated calves showed a 31.5% reduction in total mortality and a 27.5% reduction in BRD mortality compared to calves not treated with Zelnate1

Mortality at close-out: Without Zelnate vs. with Zelnate

Mortality Chart closeout

At study close-out, results for Zelnate-treated calves showed a 22.3% reduction in total mortality and a 24.5% reduction in BRD mortality compared to calves not treated with Zelnate.1

Zelnate consistently improved survivability resulting in a 22% reduction in overall death loss, regardless of on arrival or delayed MLV.1

*Explanation of terms: BRD Morbidity, % = (# of sick animals that received 1 treatment) ÷ (total # of animals); BRD Retreatment, % = (# of animals that received 2 or 3 treatments) ÷ (# of animals treated at least once); BRD Case Fatality, % = (# of animals that died from BRD) ÷ (# of animals diagnosed with BRD); BRD Mortality, % = (# of animals that died from BRD) ÷ (total # of animals); and Overall Mortality, % = (# of animals that died) ÷ (total # of animals).

Explanation of P values: P value for Pyramid® evaluated the effects of using Pyramid® during on arrival or delayed processing; P value for Zelnate evaluated if Zelnate improved health parameters independently of type of processing.

1Data on file. Bayer HealthCare Animal Health.

Was this content helpful?